THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH EGFR < 30 ML/MIN/1.73M2: FINDINGS FROM THE DAPA-CKD TRIAL

Chertow, G; Vart, P; Jongs, N; Toto, R; Gorriz, JL; Hou, FF; Mcmurray, J; Correa-Rotter, R; Rossing, P; Sjostrom, CD; Stefansson, BV; Langkilde, AM; Wheeler, DC; Heerspink, HJL

NEPHROLOGY, 2021; 26 (): 33